title: Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2 -activated platelet concentrates promoted expansion of mesenchymal stromal cells.
abstract: OBJECTIVE
  The aim of our study was to test a platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2 -activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP-R/SRGF, obtained with a low-cost procedure, is characterized by a reduced variability of growth factor release.
  
  
  METHODS
  PRP-R/SRGF is a clinical-grade quality solution obtained from CaCl2 -activated platelets. Its activity was evaluated by measuring the proliferation, the phenotype, the differentiation potential and the immunosuppressive properties of MSCs derived from bone marrow (BM) and adipose tissue (AT).
  
  
  RESULTS
  PRP-R/SRGF was more active than FBS to expand BM- and AT-derived MSCs. PRP-R/SRGF treatment did not affect the expression of typical MSCs surface markers, neither MSCs differentiation potential nor their capability to inhibit activated T-cell proliferation.
  
  
  CONCLUSIONS
  The clinical-grade PRP-R/SRGF may be used in the clinical setting for the expansion of MSCs.
authors.affiliation: Experimental Oncology 2, C.R.O. National Cancer Institute-IRCCS Aviano, Aviano, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Borghese
authors.affiliation: Unit of Stem Cells Collection and Processing Unit, CRO Aviano, National Cancer Institute-IRCCS Aviano, Aviano, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Agostini
authors.affiliation: Unit of Stem Cells Collection and Processing Unit, CRO Aviano, National Cancer Institute-IRCCS Aviano, Aviano, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Durante
authors.affiliation: Experimental Oncology 2, C.R.O. National Cancer Institute-IRCCS Aviano, Aviano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Colombatti
authors.affiliation: Unit of Stem Cells Collection and Processing Unit, CRO Aviano, National Cancer Institute-IRCCS Aviano, Aviano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Mazzucato
authors.affiliation: Experimental Oncology 2, C.R.O. National Cancer Institute-IRCCS Aviano, Aviano, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Aldinucci
mesh_terms: D000273:Adipose Tissue / Q000166:cytology; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology; D002122:Calcium Chloride / Q000494:pharmacology*; D002454:Cell Differentiation; D049109:Cell Proliferation; D002478:Cells, Cultured; D016207:Cytokines / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000378:metabolism; D010641:Phenotype; D053657:Platelet-Rich Plasma / Q000378:metabolism; D044968:Regenerative Medicine
chemical_list: D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D002122:Calcium Chloride
keywords: apheresis; cellular therapy; cytokine; mesenchymal stem cells; platelet concentrates; regenerative medicine